Physician profile
Abbey Bolden
NPI 1770114118
$1,903.00
in general payments reported to CMS, 2019-2025
21 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.91 · 2022: $294 · 2023: $614 · 2024: $638 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.39 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.30 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $342.61 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $239.56 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.44 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $158.70 | 2022-2024 | Rexulti |
| Corium, LLC | $113.97 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $65.58 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $62.63 | 2023-2025 | Fanapt, Hetlioz |
| Dynavax Technologies Corporation | $36.76 | 2024 | Heplisav-B |
| Alkermes, INC. | $26.26 | 2025 | Lybalvi |
| Pfizer INC. | $24.81 | 2022-2023 | |
| Insulet Corporation | $24.16 | 2023 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2022 | |
| Amgen INC. | $17.13 | 2023 | Otezla, Repatha |
| Lundbeck LLC | $16.46 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $16.34 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.92 | 2022 | |
| Sanofi Pasteur INC. | $14.00 | 2022 | |
| Lilly USA, LLC | $13.25 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbey Bolden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.